

MCGI Forum 2024 Disclosure to Learners

Sheila Bourgeois has no financial relationships to disclose.

Jennifer Bourne, MS has no financial relationships to disclose.

mitigated.

Dana Farengo-Clark, MS, LCGC is on the Speakers Bureau for AstraZeneca. All relevant financial relationships have been mitigated.

Lory Gaitor, BS, CCRC has no financial relationships to disclose.

Susan Halverson, BA has no financial relationships to disclose.

Petra Helbig, CCRP has no financial relationships to disclose.

Douglas Johnson, MD, MSCI is on the advisory board for Merck & Co., Bristol Myers Squibb, and Novartis; receives grant support from Bristol Myers Squibb and Incyte; and is a consultant for Pfizer Inc. and Teiko. All relevant financial relationships have been mitigated.

Jill Kolesar, PharmD, MS receives grant support from Lilly. All relevant financial relationships have been mitigated.

Richard Schilsky, MD, FACP, FSCT, FASCO is a consultant for Bryologyx, Inc., Cellworks Group, Inc., Flatiron Health, Inc., Zephyr AI, Inc., EQRx, Inc., Illumina, Inc., Syapse, Inc., and Scandion Oncology; a board member for Clarified Precision Medicine and Leap Therapeutics; and receives research funding from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Lilly, Merck & Co., Pfizer Inc., Seagen Inc., and Taiho Pharmaceutical Co., Ltd. All relevant financial relationships have been

Ryan Sullivan, MD is a consultant for Merck & Co., Bristol Myers Squibb, Marengo Therapeutics, Novartis AG, Pfizer Inc., and Replimune Group and receives research funding from Merck & Co. All relevant financial relationships have been mitigated.

David Thomas, FRACP, PhD is a researcher for Roche, SunPharma, Bayer and the Australian Unity Futures of Healthcare Fund; a speaker for Roche, Bayer and the Australian Unity Futures of Healthcare Fund; and an advisor for the Australian Unity Futures of Healthcare Fund. All relevant financial relationships have been mitigated.

Ben Westphalen, MD is a speaker for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Chugai Pharmaceutical Co., Falk, GlaxoSmithKline, Janssen Pharmaceuticals, Merck & Co., Roche Holding AG, Servier Pharmaceuticals LLC, Sirtex, and Taiho Pharmaceutical Co., Ltd; receives travel support from Bayer, Celgene, RedHill Biopharma, Roche Holding AG, Servier Pharmaceuticals LLC, and Taiho Pharmaceutical Co., Ltd; serves on the advisory board for Bristol Myers Squibb, Celgene, Rafael Pharmaceuticals, RedHill Biopharma, Roche Holding AG, and Shire/Baxalta; provides expert testimony for Janssen Pharmaceuticals; and receives a research grant from Roche Holding AG. All relevant financial relationships have been mitigated.

Jason Willis, MD, PhD receives honoraria from Bayer, receives in-kind support from Nouscom, and is a consultant for Healios K.K. All relevant financial relationships have been mitigated.